New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis

• DOI: 10.1007/s00018-020-03679-5
• Publication Date: 2020-10-17T09:02:58Z
• Authors: Ana F. Castillo; Ulises D. Orlando; Paula M. Maloberti; Jesica G. Prada; Melina A. Dattilo; Angela R. Solano; María M. Bigi; Mayra A. Ríos Med...; María T. Torres; Sebastián Indo; Graciela Caroca; Hector R. Contreras; Belkis E. Marelli; Facundo J. Salinas; Natalia R. Salvetti; Hugo H. Ortega; Pablo Lorenzano M...; Sergio Szajnman; Daniel E. Gomez; Juan B. Rodríguez; Ernesto J. Podesta
• Keywords: Male; 0301 basic medicine; Mice, Nude; Breast Neoplasms; Mice; 03 medical and health sciences; Cell Movement; Cell Line, Tumor; https://purl.org/becyt/ford/3.1; Coenzyme A Ligases; TRIPLE NEGATIVE BREAST CANCER; https://purl.org/becyt/ford/3.2; CASTRATION RESISTANT PROSTATE CANCER; Animals; Humans; Triple negative breast cancer; https://purl.org/becyt/ford/3; Enzyme Inhibitors; Cell Proliferation; Mice, Inbred BALB C; Binding Sites; Prostate; Prostatic Neoplasms; ANTI-HORMONE TREATMENT RESISTANCE; Xenograft Model Antitumor Assays; 3. Good health; Molecular Docking Simulation; Anti-hormone treatment resistance; Drug Resistance, Neoplasm; Female; Steroids; Castration resistant prostate cancer; CHEMOTHERAPY RESISTANCE; Chemotherapy resistance

Acyl-CoA synthetase 4 (ACSL4) is an isoenzyme of the fatty acid ligase-coenzyme-A family taking part in arachidonic acid metabolism and steroidogenesis. ACSL4 is involved in the development of tumor aggressiveness in breast and prostate tumors through the regulation of various signal transduction pathways. Here, a bioinformatics analysis shows that the ACSL4 gene expression and proteomic signatures obtained using a cell model was also observed in tumor samples from breast and cancer patients. A well-validated ACSL4 inhibitor, however, has not been reported hindering the full exploration of this promising target and its therapeutic application on cancer and steroidogenesis inhibition. In this study, ACSL4 inhibitor PRGL493 was identified using a homology model for ACSL4 and docking based virtual screening. PRGL493 was then chemically characterized through nuclear magnetic resonance and mass spectroscopy. The inhibitory activity was demonstrated through the inhibition of arachidonic acid transformation into arachidonoyl-CoA using the recombinant enzyme and cellular models. The compound blocked cell proliferation and tumor growth in both breast and prostate cellular and animal models and sensitized tumor cells to chemotherapeutic and hormonal treatment. Moreover, PGRL493 inhibited de novo steroid synthesis in testis and adrenal cells, in a mouse model and in prostate tumor cells. This work provides proof of concept for the potential application of PGRL493 in clinical practice. Also, these findings may prove key to therapies aiming at the control of tumor growth and drug resistance in tumors which express ACSL4 and depend on steroid synthesis.